跳到正文
Dr. Estela Rodriguez· @Latinamd · X·· 10 小时前评分70

INTERPATH-001

正文 · 机器翻译

💯% 同意。个性化辅助 mRNA 疫苗(intismeran autogene)INTerpath-001 黑色素瘤试验的部署涉及巨大的后勤问题以及潜在的 #GlobalOnc 差距,该试验今天在 #ESMO26 上公布

“新疗法的可及性不足 🟰 未兑现的承诺”

也许市场反应的是这一可及性挑战,而不是获益幅度❓#healthequity @GlopesMd

49 浏览 · 1 赞 · 2 转发 · 0 回复

会议摘要
LBA1按 Presidential Symposium I 对上

INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)

https://esmocongress.esmo.org
引用@
So the “not-so-official-anymore“ presentation is in: The melanoma vaccine works. We knew that, 82% recurrence-free at two years vs 70% with immunotherapy alone. It's built individually for each patient, the logistics are enormous: Sequence their tumor, design the vaccine, manufacture it for one person. Weeks of work that will cost a fortune. A treatment like that doesn't scale to most of the world. It scales to countries that can afford a factory run per patient. I live in a country which happens to be able to afford that, most countries can’t. Melanoma kills people everywhere. This will reach a fraction of them. Solving cancer and solving access are two different problems. We just got better at the first one.
在 X 查看被引用的帖子

来源:Dr. Estela Rodriguez · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org